Latest Royalty Pharma Stories

2014-05-06 08:42:51

Jim Reddoch, PhD, Royalty Pharma Executive Vice President for Research and Investments Joins Avillion Board LONDON and NEW YORK, May 6, 2014 /PRNewswire/ -- Avillion LLP, a company focused on co-development and financing of late-stage pharmaceutical candidates from Phase 3 clinical development through marketing approval, announced that Royalty Pharma has become an investor, joining Abingworth LLP and Clarus Ventures. Royalty Pharma will be represented on the Avillion Board by Jim...

2014-01-06 08:26:28

NEW YORK, Jan. 6, 2014 /PRNewswire/ -- Royalty Pharma announced today that it has acquired an additional interest in the earn-out payable to the former shareholders of Fumapharm AG for $510 million in cash. (Logo: http://photos.prnewswire.com/prnh/20130812/NY62264LOGO) The Fumapharm earn-out primarily represents an indirect interest in sales of Biogen Idec's TECFIDERA® (dimethyl fumarate), an oral therapeutic for the treatment of relapsing-forms of multiple sclerosis. The...

Word of the Day
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'